- Home
- TSVT vs GUTS Comparison
TSVT vs GUTS Comparison
Compare TSVT & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSVT
- GUTS
- Stock Information
- Founded
- TSVT 2021
- GUTS 2010
- Country
- TSVT United States
- GUTS United States
- Employees
- TSVT N/A
- GUTS N/A
- Industry
- TSVT Biotechnology: Pharmaceutical Preparations
- GUTS
- Sector
- TSVT Health Care
- GUTS
- Exchange
- TSVT Nasdaq
- GUTS NYSE
- Market Cap
- TSVT 128.5M
- GUTS 110.1M
- IPO Year
- TSVT N/A
- GUTS 2024
- Fundamental
- Price
- TSVT $2.45
- GUTS $1.82
- Analyst Decision
- TSVT Buy
- GUTS Buy
- Analyst Count
- TSVT 6
- GUTS 2
- Target Price
- TSVT $10.40
- GUTS $18.00
- AVG Volume (30 Days)
- TSVT 449.7K
- GUTS 373.0K
- Earning Date
- TSVT 03-04-2025
- GUTS 02-02-2025
- Dividend Yield
- TSVT N/A
- GUTS N/A
- EPS Growth
- TSVT N/A
- GUTS N/A
- EPS
- TSVT N/A
- GUTS N/A
- Revenue
- TSVT $45,620,000.00
- GUTS $97,000.00
- Revenue This Year
- TSVT N/A
- GUTS N/A
- Revenue Next Year
- TSVT $36.09
- GUTS N/A
- P/E Ratio
- TSVT N/A
- GUTS N/A
- Revenue Growth
- TSVT N/A
- GUTS N/A
- 52 Week Low
- TSVT $2.35
- GUTS $1.74
- 52 Week High
- TSVT $6.40
- GUTS $14.50
- Technical
- Relative Strength Index (RSI)
- TSVT 35.00
- GUTS 41.31
- Support Level
- TSVT $2.36
- GUTS $1.77
- Resistance Level
- TSVT $2.53
- GUTS $2.10
- Average True Range (ATR)
- TSVT 0.18
- GUTS 0.16
- MACD
- TSVT 0.01
- GUTS -0.01
- Stochastic Oscillator
- TSVT 13.82
- GUTS 9.18
About TSVT 2seventy bio Inc.
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.